Just months after winning European approval for a biosimilar of Remicade, Korea's Celltrion says its CEO--and largest shareholder--faces a formal investigation for stock manipulation. The country's Financial Services Commission has asked prosecutors to step in, reports Bloomberg, possibly complicating the planned sale of Kim Joon Seok's stake in the manufacturer. Rumors had been circulating that AstraZeneca ($AZN) was interested in snagging the stock. Story